Advanced Primary Liver Cancer
Conditions
Brief summary
Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
Detailed description
Patients with advanced primary liver cancer will be enrolled in the trial , then the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .The purpose of the study is to evaluate the effect and safety of the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment in the treatment of advanced primary liver cancer
Interventions
DRUGElemene Injection/Elemene Oral Emulusion
Sponsors
Dalian Holley Kingkong Pharmaceutical Co., Ltd
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18-75 years old，No limit on gender * Patients who are confirmed Locally advanced or metastatic primary liver cancerin accordance with the clinical diagnostic criteria , or by pathological histology or cytology examination, Patients who are unable to accept surgery,radiofrequency ablation、TACE and local therapy ，orLocal treatment progress failed * have systematic treatment before( including systematic chemotherapy and/or molecular targeted therapy) , but the treatment was unsuccessed and the tumor progress * According to RECIST V1.1，1at least has one measurable lesions * ECOG Score ≤2 * Patients who have primary liver cancer with Child - Pugh liver function grade rating A or better B(score\<=7) * Laboratory inspection basically meets the following requirements： Blood test：a. Hb\>=90g/L(without blood transfusion within 14 days), b. ANC\>=1.5×10\^9/L, c. PLT\>=60×10\^9/L. Biochemical test：a. ALB\>=29g/L(without blood transfusion within 14 days), b. ALT and AST \<=5ULN, c. TBIL\<=2ULN, d. Cr\<=1.5ULN. Blood Coagulation function:PT\<=ULN+6seconds. * Life expectancy of at least 3 months * Subjects join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up.
Exclusion criteria
* Patients have other anti-cancer treatment ， including α-IFN，Arsenious Acid Injection and other Traditional Chinese Medicine Patent Prescription for treating cancer * In the past or at the same time,patients were diagnosed with other malignant tumor which have not been cured. As for skin basal cell carcinoma and cervical carcinoma in situ,they can be excepted * Patients with severe acute infection and cann't be controled , Chronic suppurative infection , body temperature\>=39℃ ， Pleural effusion（medium and large） combined with infection * Women who is pregnant or during breast feeding and not willing to contraception during the test * Coagulation dysfunction(PT\>16 seconds ， APTT\>43 seconds , TT\>21 seconds , Fib\<2g/L) , With bleeding tendency or the presence of vital organ thrombosis (lung, brain) is receiving thrombolytic or anticoagulant therapy * With a mental illness, or has a history of drugs abuse * Patients accepted any experimental drugs in the past 4 weeks * Other reasons the researchers think not suitable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DCR and/or 6-months survival rate | 6 months | Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease/ |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 1year | Objective response rate.The proportion of patients who had a best response rating of complete response and partial response. |
| PFS | 1 year | Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause |
| OS | 3 year | Overrall survival.The time of patient from randomization to death caused by any cause |
| QLQ | 3 year | Quality of Life Questionnaire Core 30 |
| the rate of incidence of adverse events | 3 year | NCI CTC AE 4.03 |
Countries
China
Contacts
Primary ContactShukui Qin
Outcome results
None listed